Replies to post #425012 on Amarin Corp Plc (AMRN)

[Downtownguy]

Hi Lizzy nice to hear from you. Scroll back through today’s posts…North…JRoon…Steven, etc seemed to have confirmed the news

[JRoon71]

Lizzy, the CVS/Caremark change does not effect Medicare policies.

[Number sleven]

Lizzy, Do a Google search for formulary changes at Aetna July 1st 2024. Without much work you will find a PDF that shows Vascepa is being dropped. Icosapent ethyl is being added. You are correct that this change has no effect on Medicare part D coverage.
Sleven,

[djks]

I found this - perhaps it will answer your question.

https://ih.advfn.com/stock-market/NASDAQ/amarin-AMRN/stock-news/93979625/form-8-k-current-report
--
Item 7.01 Regulation FD Disclosure

The Company has been informed by a large national pharmacy benefit manager (“PBM”) that, effective July 1, 2024, the PBM intends to no longer cover VASCEPA as the exclusive icosapent ethyl product for its Commercial national formularies and will be transitioning VASCEPA to not covered as of July 1, 2024. Currently, VASCEPA volume through these formularies represents approximately 25% of aggregate U.S. VASCEPA prescription volume. This decision does not impact VASCEPA coverage within Medicare Part D formularies of the PBM.

The information set forth under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

--
djks